Johnson & JohnsonHorsham, Pennsylvania, United States
0257: Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Sunday, October 26, 202510:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
